Zevra adds Edsivo for vEDS to its rare disease portfolio in new deal
Zevra Therapeutics is adding Edsivo (celiprolol), an experimental therapy for vascular Ehlers-Danlos syndrome (vEDS), to its clinical pipeline of rare diseases, as part of an agreement in which the company will acquire Acer Therapeutics, The new deal means Zevra will take over the ongoing Phase…